H3Africa Collaborative Centers

AWI-Gen 2: Genomic and Environmental Risk Factors for Cardiometabolic Disease in Africans


The Goal

AWI-Gen is working to understand how genes, environment, and lifestyle affect cardiovascular and metabolic health across Africa and to uncover new insights that could help to improve the health of Africans.

Principal Investigator:

Prof Michele Ramsay

University of Witwatersrand


The Problem

Due to advances in the field of genetics and genomics, researchers now have the ability to understand how one’s DNA and their environment can play a role in their susceptibility to obesity, hypertension, and diabetes – but only in western populations. African populations have been routinely omitted from this fundamental research, keeping them from accessing basic public health strategies.

Project Strategy

  1. Survey 12,000 participants across the continent for information regarding lifestyle, environment, and medical history.
  2. Collect blood and urine samples from participants to measure genomic and metabolic health factors.
  3. Use this information to explore genetic contributions and gene-by-environment interactions on susceptibility for traits like obesity, hypertension and diabetes.
  4. Use insights to support development of better prevention and treatment strategies and to inform public policy.

Outcomes to Date

So far, AWI-Gen has found that obesity disproportionately affects women in southern and eastern Africa and is linked to increased prevalence of diabetes. There is regional variation in the prevalence of hypertension, with a lack of awareness of high blood pressure,. Although some are aware of their status and on medication, their blood pressure remains poorly controlled. Genetic studies have shown that people from the same region and ethnicity tend to cluster together, and that there are differences between the people from western, eastern and southern Africa. Geographic isolation and local adaption to their environments may in part account for these differences.

Project Sites

A. South Africa, WITS Health Consortium, University of the Witwatersrand

B. South Africa, University of Limpopo

C. Ghana, Navrongo Health Research Center

D. Burkina Faso, Clinical Research Center of Nanoro

E. Kenya, African Population and Health Research Center

Non-African Collaborators
USA: Harvard University, Stanford University, University of Colorado
UK: University of Bristol, University of Leicester & Wellcome Trust Sanger Institut

October 16, 2018

AWI-GEN 2: Genomic and Environmental Risk Factors for Cardiometabolic Disease in Africans

AWI-Gen is the Africa Wits-INDEPTH partnership for Genomic Studies, an NIH funded and university supported Collaborative Center of the Human Heredity and Health in Africa
April 4, 2018

African Collaborative Center for Microbiome and Genomics Research (ACCME)

The African Collaborative Center for Microbiome and Genomics Research (ACCME) leverages advanced research methods, technologies and international partnerships to engage African scientists
April 4, 2018

Burden, spectrum and etiology of type 2 diabetes in sub-Saharan Africa

Our primary aim is to assess the burden and aetiological characteristics of T2D in adults in SSA using large scale population based approaches. To achieve this, we aim to develop a large scale epidemiological and genomic research resource comprising up to 12,000 cases of T2D and a population based cross-sectional study of up to 12,000 participants drawn from diverse sampling frames across SSA. Scientific objectives:
April 4, 2018

TrypanoGEN: An integrated approach to the identification of genetic determinants of susceptibility to trypanosomiasis

The over-arching aim of this network is to improve the health of people living in some of the poorest countries in the world that carry a disproportionate burden of infectious diseases. Despite their importance, the study of many tropical diseases has lagged behind that of diseases of developed countries.
April 4, 2018

The RHDGen Network: Genetics of rheumatic heart disease and molecular epidemiology of Streptococcus pyogenes pharyngitis

Rheumatic heart disease (RHD) results from a harmful response of the immune system to a bacterium called Streptococcus pyogenes or Group A Streptococcus (GAS). Although the development of RHD can be prevented by the treatment of GAS infection with penicillin, this has not been successful in